Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.

Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 (COVID-19): a multi-hospital cohort study.

Open access

Abstract

Background: Antibacterials may be initiated out of concern for bacterial coinfection in coronavirus disease 2019 (COVID-19). We determined prevalence and predictors of empiric antibacterial therapy and community-onset bacterial coinfections in hospitalized patients with COVID-19. Methods: A randomly sampled cohort of 1705 patients hospitalized with COVID-19 in 38 Michigan hospitals between 3/13/2020 and 6/18/2020. Data were collected on early (within 2 days of hospitalization) empiric antibacterial therapy and community-onset bacterial coinfections (positive microbiologic test ≤3 days). Poisson generalized estimating equation models were used to assess predictors. Results: Of 1705 patients with COVID-19, 56.6% were prescribed early empiric antibacterial therapy; 3.5% (59/1705) had a confirmed community-onset bacterial infection. Across hospitals, early empiric antibacterial use varied from 27% to 84%. Patients were more likely to receive early empiric antibacterial therapy if they were older (adjusted rate ratio [ARR]: 1.04 [1.00–1.08] per 10 years); had a lower body mass index (ARR: 0.99 [0.99–1.00] per kg/m2), more severe illness (eg, severe sepsis; ARR: 1.16 [1.07–1.27]), a lobar infiltrate (ARR: 1.21 [1.04–1.42]); or were admitted to a for-profit hospital (ARR: 1.30 [1.15–1.47]). Over time, COVID-19 test turnaround time (returned ≤1 day in March [54.2%, 461/850] vs April [85.2%, 628/737], P < .001) and empiric antibacterial use (ARR: 0.71 [0.63–0.81] April vs March) decreased. Conclusions: The prevalence of confirmed community-onset bacterial coinfections was low. Despite this, half of patients received early empiric antibacterial therapy. Antibacterial use varied widely by hospital. Reducing COVID-19 test turnaround time and supporting stewardship could improve antibacterial use.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciaa1239

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Early empiric antibiotic treatment in hospitalized patients with COVID-19, by hospital (N = 32 hospitals; 1667 patients). Each bar represents 1 hospital. The number of COVID-19–positive cases included per hospital is shown at the top of each bar. Arrows indicate for-profit hospitals. Hospitals with less than 10 included COVID-19–positive cases are not shown (n = 6). Abbreviations: COVID-19, coronavirus disease 2019; MRSA, methicillin-resistant Staphylococcus aureus.
Figure 1. Early empiric antibiotic treatment in hospitalized patients with COVID-19, by hospital (N = 32 hospitals; 1667 patients). Each bar represents 1 hospital. The number of COVID-19–positive cases included per hospital is shown at the top of each bar. Arrows indicate for-profit hospitals. Hospitals with less than 10 included COVID-19–positive cases are not shown (n = 6). Abbreviations: COVID-19, coronavirus disease 2019; MRSA, methicillin-resistant Staphylococcus aureus.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 28 references

Research works printed but not linked: 2

  1. Lehmann, 2020, Community acquired co-infection in COVID-19: a retrospective observational experience, Clin Infect Dis
  2. Vaughn, 2019, The association of antibiotic stewardship with fluoroquinolone prescribing in Michigan hospitals: a multi-hospital cohort study, Clin Infect Dis, 69, 1269, 10.1093/cid/ciy1102 · DOI

Cited by

See all 396

Metadata

Authors
Vaughn, V. M., Gandhi, T. N., Petty, L. A., Patel, P. K., Prescott, H. C., Malani, A. N., Ratz, D., McLaughlin, E., Chopra, V., & Flanders, S. A.
Affiliations
  • University of Michigan (US)
  • Trinity Health Michigan (US)
Corresponding author
Vaughn, Valerie M
Venue
Clinical Infectious Diseases
Published
2020-08-21
Volume
72
Issue
10
Pages
e533-e541
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W3081368778
Cited by
396
References
28
Citations by year
2026: 19 · 2025: 15 · 2024: 42 · 2023: 90 · 2022: 111 · 2021: 103 · 2020: 14
FWCI
10.43
Type
journal article
Language
en
Open access
Locations
  • Clinical Infectious Diseases (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Agency for Healthcare Research and Quality
Topics
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
  • Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Nosocomial Infections in ICU
Keywords
COVID-19 pandemic, SARS-CoV-2, bacterial co-infection, hospitalized patients, test turnaround time, hospital variation, for-profit hospitals, body mass index, severe sepsis, antibiotic prescribing, COVID-19 testing capacity, Michigan hospitals, Michigan
MeSH terms
COVID-19, SARS-CoV-2, Anti-Bacterial Agents, Hospitalization, Hospitals, Humans, Michigan, Cohort Studies, Coinfection

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 (COVID-19): a multi-hospital cohort study. https://app.cochat.ai/papers/10.1093/cid/ciaa1239
The paper
Vaughn, V. M., Gandhi, T. N., Petty, L. A., Patel, P. K., Prescott, H. C., Malani, A. N., Ratz, D., McLaughlin, E., Chopra, V., & Flanders, S. A. (2021). Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 (COVID-19): a multi-hospital cohort study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaa1239

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.